Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00129038
Status:
COMPLETED
Last Update Posted:
2013-10-29
First Post:
2005-08-10
Brief Title:
Modified-release DipyridamoleAspirin 200mg25mg bd Versus Aspirin 75mg in Aspirin-resistant Patients
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Randomised Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release DipyridamoleAspirin 200mg25 mg bd Asasantin Retard With Aspirin 75 mg qd in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to assess whether adding modified-release dipyridamole to aspirin Asasantin Retard has measurable effects on markers of platelet function for example platelet aggregation in patients with cardiovascular disease who are known to be resistant to aspirin alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None